Know Cancer

or
forgot password

A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination With Pemetrexed (Alimta®) Versus Pemetrexed Alone in Patients With Locally-Advanced or Metastatic NSCLC


Phase 3
18 Years
N/A
Open (Enrolling)
Both
Non Small Cell Lung Cancer, Lung Cancer

Thank you

Trial Information

A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination With Pemetrexed (Alimta®) Versus Pemetrexed Alone in Patients With Locally-Advanced or Metastatic NSCLC


This randomized phase III non-small cell lung cancer clinical trial is studying the effect
of Alimta (pemetrexed) plus vandetanib to see how well the combination works compared to
Alimta (pemetrexed) alone in patients who have previously been treated for non-small cell
lung cancer (NSCLC).


Inclusion Criteria:



- Provision of informed consent

- Female or male aged 18 years or above

- Histologic or cytologic confirmation of locally advanced or metastatic NSCLC (stage
IIIB or IV) on entry into study

- Failure of 1st line anti-cancer therapy (either radiological documentation of disease
progression or due to toxicity) or subsequent relapse of disease following 1st line
therapy

- WHO Performance status 0 - 2

- One or more measurable lesions at least 10 mm in the longest diameter (LD) by spiral
CT scan or 20 mm with conventional techniques according to RECIST criteria.
Previously irradiated lesions will not be considered measurable.

- Life expectancy of 12 weeks or longer

- Negative pregnancy test for women of childbearing potential only

Exclusion Criteria:

- Mixed small cell and non-small cell lung cancer histology

- Patients have received 2nd-line or subsequent anti-cancer therapy

- Prior treatment with pemetrexed

- Prior treatment with VEGFR TKIs (previous treatment with bevacizumab [Avastin] is
permitted)

- Known or suspected brain metastases or spinal cord compression, unless treated at
least 4 weeks before entry, and stable without steroid treatment for 10 days

- The last radiation therapy within 4 weeks before the start of study therapy, not
including local palliative radiation

- The last dose of prior chemotherapy or other anti-cancer therapy is discontinued less
than 3 weeks before the start of study therapy (6 weeks for nitrosoureas, mitomycin,
and suramin)

- Major surgery within 4 weeks before entry, or incompletely healed surgical incision

- Neutrophils <1.5 x 109/L or platelets <100 x 109/L

- Serum bilirubin >1.5 x the upper limit of reference range (ULRR)

- Creatinine clearance <50 ml/min calculated by either Cockcroft -Gault, 24 hours urine
collection, EDTA scan or other validated methods

- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 x ULRR in the
absence of liver metastases, or > 5 x ULRR in the presence of liver metastases

- Alkaline phosphatase (ALP) >2.5 x ULRR in the absence of liver metastases, or >5 x
ULRR in the presence of liver metastases

- Current active gastrointestinal disease that may affect the ability of the patient to
absorb ZD6474 or tolerate diarrhoea

- Evidence of severe or uncontrolled systemic disease or any concurrent condition which
in the investigator's opinion makes it undesirable for the patient to participate in
the study or which would jeopardize compliance with the protocol

- Any unresolved toxicity greater than CTCAE Grade 2 from previous anti-cancer therapy

- Significant cardiovascular event (e.g., myocardial infarction, superior vena cava
[SVC] syndrome), New York Heart Association [NYHA] classification of heart disease ≥2
within 3 months before entry, or presence of cardiac disease that in the opinion of
the Investigator increases the risk of ventricular arrhythmia

- History of arrhythmia (multifocal premature ventricular contractions [PVCs],
bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation)
which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained
ventricular tachycardia. Atrial fibrillation, controlled on medication is not
excluded

- Congenital long QT syndrome or 1st degree relative with unexplained sudden death
under 40 years of age

- QT prolongation with other medications that required discontinuation of that
medication

- Presence of left bundle branch block (LBBB)

- QTc with Bazett's correction unmeasurable or ≥ 480 msec on screening ECG (Note: If a
patient has QTc interval ≥480 msec on screening ECG, the screen ECG may be repeated
twice [at least 24 hours apart]. The average QTc from the three screening ECGs must
be <480 msec in order for the patient to be eligible for the study) Patients who are
receiving a drug that has a risk of QTc prolongation are eligible if QTc is <460
msec.

- Potassium <4.0 mmol/L despite supplementation; serum calcium (or ionized or adjusted
for albumin), or magnesium out of normal range despite supplementation

- Women who are pregnant or breast-feeding

- Any concomitant medications that may cause QTc prolongation or induce Torsades de
Pointes or induce CYP3A4 function. Drugs that have a risk of QTc prolongation, that
in the investigator's opinion cannot be discontinued, are allowed, but only of the
QTc is <460 msec

- Hypertension not controlled by medical therapy (systolic blood pressure greater than
160 millimetre of mercury [mmHg] or diastolic blood pressure greater than 100 mmHg)

- Previous or current malignancies of other histologies within the last 5 years, with
the exception of in situ carcinoma of the cervix and adequately treated basal cell or
squamous cell carcinoma of the skin

- Treatment with a non-approved or investigational drug within 30 days before Day 1 of
study treatment

- Concomitant use of yellow fever vaccine or any live attenuated vaccines

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Progression-Free Survival (PFS) in the Overall Population

Outcome Description:

Median time (in weeks) from randomisation until objective disease progression or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment

Outcome Time Frame:

RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomisation until objective progression

Safety Issue:

No

Principal Investigator

Peter Langmuir, MD

Investigator Role:

Study Director

Investigator Affiliation:

AstraZeneca

Authority:

United States: Food and Drug Administration

Study ID:

D4200C00036

NCT ID:

NCT00418886

Start Date:

January 2007

Completion Date:

December 2012

Related Keywords:

  • Non Small Cell Lung Cancer
  • Lung Cancer
  • NSCLC
  • Non Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location

Research SiteMesa, Arizona  
Research SiteDanbury, Connecticut  
Research SiteWashington, District of Columbia  
Research SiteBoca Raton, Florida  
Research SiteAlbany, Georgia  
Research SiteArlington Heights, Illinois  
Research SiteAmes, Iowa  
Research SiteAshland, Kentucky  
Research SiteBangor, Maine  
Research SiteBaltimore, Maryland  
Research SiteBeverly, Massachusetts  
Research SiteAlbany, New York  
Research SiteAsheville, North Carolina  
Research SiteAkron, Ohio  
Research SiteCharleston, South Carolina  
Research SiteAbilene, Texas  
Research SiteIvins, Utah